Titan Pharmaceuticals Inc
NASDAQ:TTNP
Operating Margin
Titan Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
6.6m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
660.9B USD |
42%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
424.9B USD |
26%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.1B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
182B GBP |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
46%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
194.2B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
38%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143B USD |
29%
|
Titan Pharmaceuticals Inc
Glance View
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Titan Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet